Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus

Background: In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal was established to develop an evidence-based guideline for treatment of hyperglycemia in T2DM. Methods: MEDLINE (via PubMed) was searched for randomized clinical trials, meta-analyses, and observational studies related to diabetes treatment. When there was insufficient high-quality evidence, expert opinion was sought. Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation and the level of evidence were determined using predefined criteria. Results and conclusions: In non-pregnant adults, the recommended HbA1c target is below 7%. Higher levels are recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended at all phases of treatment. Metformin is the first choice when HbA1c is 6.5-7.5%. When HbA1c is 7.5-9.0%, dual therapy with metformin plus an SGLT2i and/or GLP-1RA (first-line antidiabetic agents, AD1) is recommended due to cardiovascular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple therapy should be considered when HbA1c remains above target. In patients with clinical or subclinical atherosclerosis, the combination of one AD1 plus metformin is the recommended first-line therapy to reduce cardiovascular events and improve blood glucose control. In stable heart failure with low ejection fraction ( 30 mL/min/1.73 m2, metformin plus an SGLT-2i is recommended to reduce cardiovascular mortality and heart failure hospitalizations and improve blood glucose control. In patients with diabetes-associated chronic kidney disease (CKD) (eGFR 30-60 mL/min/1.73 m2 or eGFR 30-90 mL/min/1.73 m2 with albuminuria > 30 mg/g), the combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria and improve blood glucose control. In patients with severe renal failure, insulin-based therapy is recommended to improve blood glucose control. Alternatively, GLP-1RA, DPP4i, gliclazide MR and pioglitazone may be considered to reduce albuminuria. In conclusion, the current evidence supports individualizing anti-hyperglycemic treatment for T2DM.This article publication was funded by Sociedade Brasileira de Diabetes (SBD)

Problemas relacionados aos medicamentos em idosos fragilizados da Zona da Mata Mineira, Brasil

OBJETIVO: Identificar os principais problemas de saúde, o perfil de utilização de medicamentos e os problemas relacionados aos medicamentos (PRMs) envolvidos no tratamento de idosos fragilizados da Zona da Mata Mineira. MÉTODOS: Foram avaliados prontuários de 260 idosos atendidos pelo Centro Mais Vida, Juiz de Fora-MG, entre agosto e setembro de 2010. As doenças foram agrupadas de acordo com a Classificação Internacional de Doenças - 10ª revisão, os medicamentos de acordo com o Anatomical Therapeutic Chemical Classification System e os PRMs de acordo com o Método Dáder. RESULTADOS: Observou-se que 73,8% dos idosos eram do sexo feminino e 42,7% possuíam entre 60 e 69 anos. Foram constatadas 1.300 doenças, sendo 31,07% do aparelho circulatório, 19,85% endócrinas, nutricionais e metabólicas e 13,46% do sistema osteomuscular e tecido conjuntivo. Dos 1.737 medicamentos, os mais prevalentes foram os do sistema cardiovascular (42,8%), seguidos pelos do trato alimentar e metabolismo (23,7%) e pelos do sistema nervoso (18,2%). Do total de medicamentos, 53,9% apresentaram algum PRM, sendo o PRM 1 (não utilização da medicação necessária) o mais frequente (37,4%). CONCLUSÃO: Os resultados evidenciam a necessidade da revisão dos esquemas terapêuticos dos idosos, visando o uso racional e efetivo dos medicamentos. Os dados apontam, ainda, a necessidade de aprofundar estudos de avaliação de riscos de PRM nessa população